Latest News
Conference Coverage
New research confirms recommendations on COVID-19 boosters in MS
“Even MS patients whose B cells were depleted from circulation with ocrelizumab can mount immune responses to COVID-19 vaccines.”
Conference Coverage
Combo thrombolytic approach fails to reduce ICH in stroke
Although there were promising signs of a potential reduced bleeding risk in intracranial hemorrhage, the DUMAS study showed no benefit on the...
Conference Coverage
Race and gender: Tailoring treatment for sleep disorders is preferred and better
Sleep disparities are multifactorial and it is important to focus on social determinants of poor sleep.
Latest News
Locked-in syndrome malpractice case ends with $75 million verdict against docs
“Cases that elicit significant and sometimes decisive sympathy include locked-in syndrome, permanent vegetative state, injury to the sexual or...
Conference Coverage
GFAP may complement NfL as MS biomarker
GFAP is linked to progression while NfL is linked to inflammation.
Feature
Scientists identify new genetic links to dyslexia
“Only a small genomewide study of dyslexia existed before ours,” says author of a new study.
From the Journals
Dementia prevalence study reveals inequities
Researchers say inequities likely stem from structural racism and income inequality.
From the Journals
Kidney function may help docs pick antiplatelet mix after stroke
Ticagrelor–aspirin compared with clopidogrel-aspirin reduced risk for recurrent stroke with no substantial increase in severe or moderate bleeding...
Conference Coverage
Intensive BP lowering harmful in acute ischemic stroke: ENCHANTED2/MT
“This result is not what we expected, but it is a definitive result and gives us a lower safety margin for blood pressure in acute ischemic stroke...
Conference Coverage
Collateral flow flags stroke patients for late thrombectomy
The MR CLEAN-LATE trial shows patients selected for thrombectomy on the presence of collateral flow had a greater chance of a better functional...
Conference Coverage
Can MS be stopped early in its tracks?
Dimethyl fumarate reduced the risk of a first acute or progressive event related to CNS demyelination by more than 80%, compared with placebo.